Soliris (eculizumab) has been approved in China for the treatment of adult patients with refractory generalised myasthenia gravis (gMG) who are anti-acetyl...
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial1 is being led by Lanhzou Biotechnique Development wi...
SomaLogic, Inc., a leader in proteomics technology, announced today their collaboration with Citogen, the Longwood Group’s customer services and supp...
HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally. HBM1020 was generated fro...
STP122G is part of the Group's GalAhead™ Factor XI RNAi therapeutic program, which has applications across a broad range of disease indications such ...
This marks the second BTD granted to olverembatinib by the CDE, with the first one granted in March 2021 for the treatment of patients with chronic-phase c...
— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 — — NDA includes results from the Phase III FRESCO...
State-of-the-art cryogenic freezers alongside material transfer equipment have been installed that are designed to retain the integrity of investigational ...
Humanetics Biomed is a Contract Development Manufacturing Organisation (CDMO) that combines the best biomedical technologies from Humanetics; with the tech...
The cell & gene therapy (CGT) CDMO has an established global footprint with two GMP manufacturing facilities in China and its headquarters in Vancouver...
DF-006 is a first-in-class, orally administered ALPK1 agonist immunomodulator that potently stimulates local, innate immunity in the liver, leading to a ro...
GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, has expanded its primary manufacturing facil...
WuXi Biologics is the manufacturing partner of InflaRx for Gohibic (vilobelimab), a first-in-class monoclonal anti-C5a antibody. InflaRx received emerge...
"We are very pleased to achieve full patient enrollment in Asia ahead of schedule, which brings Everest an important step closer to offering etrasimod to p...
© 2025 Biopharma Boardroom. All Rights Reserved.
